{"entity":{"id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of pembrolizumab in lung cancer, run by University of Washington, now recruiting.","summary":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT05570825 by University of Washington, with a registry enrolment figure of 30 participants, started 2023-04-06 and due to reach its primary completion in 2027-07-01. Interventions recorded: Biopsy; Biospecimen Collection; Computed Tomography; CXCR1/2 Inhibitor SX-682; Magnetic Resonance Imaging; Pembrolizumab; Positron Emission Tomography. Conditions listed: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Best objective response rate. Lung eligibility wording from the registry: \"* Pathologically or cytologically confirmed non-small cell lung cancer with no known oncogenic EGFR mutation, ALK rearrangement, ROS1 rearrangement or RET rearrangement\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05570825","url":"https://clinicaltrials.gov/study/NCT05570825"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05570825","phase":"2","setting":"A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer","sponsor":"University of Washington","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05570825/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}